Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects

NCT07219030 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07219030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
October 8, 2025
Completion date
December 31, 2026
Enrollment
52 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer